FDA Brief

Warning letters Drugs

FDA warning letter to

Flowchem Pharma Private Limited

High riskIssued Mar 11Posted Mar 17Center for Drug Evaluation and Research (CDER)

FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

What happened

FDA inspected Flowchem Pharma's API plant in Hindupur, Andhra Pradesh, from September 8 to 12, 2025. Investigators found equipment marked clean that held residue, rust and unidentified liquids, open bags of API material stored outside next to construction, a raw-material solution with brown particles in it, unvalidated impurity test methods, and raw materials accepted on supplier certificates without identity testing. FDA placed all drugs offered for import from the firm on Import Alert 66-40 on January 22, 2026.

What FDA found

  1. Equipment used to make several products was not cleaned properly: it held residue, rust and unidentified liquids while marked as clean and ready to use.

    21 CFR 211.67 (cleaning and maintenance of equipment)
  2. Materials and intermediates were stored without protection, including open bags of API left outside near construction, and a solution was visibly contaminated with brown particles.

    21 CFR 211.42 / 211.130 (facility and material handling to prevent contamination)
  3. The company did not establish an impurity profile, its organic-impurity test method was not validated, unknown impurity peaks were not quantified, and a 2021 reference standard was never qualified.

    21 CFR 211.160 / 211.194 (scientifically sound test methods and reference standards)
  4. The company did not test the identity of each incoming raw material batch and relied on supplier certificates of analysis without qualifying the suppliers.

    21 CFR 211.84 (testing and approval of components; supplier qualification)
  5. The quality unit was not given or did not use enough authority and resources to assure drug quality.

    21 CFR 211.22 (quality control unit responsibilities)

What FDA wants

FDA tells the firm to correct the deviations promptly and reply in writing within 15 working days with corrective action plans, including independent reviews of cleaning, laboratory, material and supplier systems. FDA also recommends hiring a qualified CGMP consultant to run a six-system audit.

Who should pay attention

  • brands and dosage-form makers buying APIs from this contract manufacturer
  • U.S. finished-drug manufacturers listing this firm as an API supplier
  • supply chain and vendor qualification teams sourcing from Indian API plants

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium